Published on November 18, 2026
CAR T Cell-induced Interferon Gamma Enhances MHC Class I Expression and Sensitizes Neuroblastoma to TCR-engineered T Cell Therapy
by Alex Kadhim
Authors from Charité University Medical Center Berlin, German Cancer Consortium, the Princess Máxima Center for Pediatric Oncology in Utrecht, and University Hospital Essen have demonstrated that neuroblastoma evades T cell receptor (TCR) recognition by keeping major histocompatibility complex (MHC) class I low. However, chimeric antigen receptor (CAR) T cells attacking the same tumor release enough interferon gamma (IFNγ) to force that expression back up. Published in Frontiers in Immunology, the study supports giving CAR and TCR T cell products in sequence.
Neuroblastoma is the most common extracranial solid tumor of childhood and arises from neural crest precursors with intrinsically reduced MHC class I, which limits TCR-engineered therapy against antigens such as NY-ESO-1. Antigen expression is also heterogeneous, so CAR T cells leave antigen-negative subpopulations behind. The authors screened 27 neuroblastoma cell lines for surface HLA-A,B,C before and after IFNγ exposure, then used LAN-1 cells as the model. Primary human T cells were engineered either with an L1CAM-targeted CAR, knocked into the TRAC locus by non-viral CRISPR/Cas9, or with an HLA-A*02:01-restricted NY-ESO-1 TCR. Killing was quantified by IncuCyte real-time assays, alone or sequentially, including against 1:1 mixtures of parental and CRISPR-generated L1CAM-knockout cells, with confirmation in NSG xenografts and a syngeneic GD2-CAR model.
IFNγ raised HLA-A,B,C in most lines, with NB69 and SK-N-SH resistant. NY-ESO-1 TCR T cells, enriched from 22.4% ± 13.04% to 74.7% ± 16.9% (n = 5), killed poorly alone but produced a 92.8% ± 0.34% reduction in tumor expansion after IFNγ pretreatment (p = 0.0597, n = 3). CAR T cell pretreatment gave a 76.5% ± 14.7% reduction (n = 3), with higher CD25 and CD137 expression (p = 0.0204 and p = 0.0112) and HLA-A02 upregulation (p = 0.0003). In mixed cultures, sequential treatment cut expansion by 59.8% ± 10.6% in parental and 87.4% ± 9.8% in L1CAM-knockout cells, converting antigen-negative cells into TCR targets. In vivo HLA-A*02 induction peaked by day 7 without reaching significance. Thus, sequential CAR and TCR T cell therapy addresses two barriers at once in preclinical neuroblastoma models, using CAR-derived IFNγ to restore MHC class I and to bring antigen-negative tumor cells within reach of TCR-mediated killing.
Reference
Vitali A, Padlo J, Caramel C, et al. CAR T cell-induced interferon gamma enhances MHC class I expression and sensitizes neuroblastoma to TCR-engineered T cell therapy. Front Immunol. 2026;17:1901504. https:doi.org/10.3389/fimmu.2026.1901504